These innovative compounds represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://antonbplu105930.blogsuperapp.com/39686994/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide